Capital IP closes inaugural $100 million investment vehicle
Capital IP Investment Partners, LLC (“Capital IP” or “CapIP”), an investment firm focused on structured investment opportunities in the life sciences and technology sectors, announced today that it has closed its inaugural $100 million investment vehicle with the backing of a leading institutional partner.
CapIP is focused on providing flexible capital solutions to a broad spectrum of companies spanning biopharma, medical devices, medical tools and diagnostics, and IT software, services and hardware. Capital IP seeks to create highly customized investment structures that offer fast-growing companies greater flexibility than traditional sources of growth capital with minimal equity dilution. These structured investments also offer Capital IP’s investors reduced downside, multiple sources of investment return, and limited correlation to other asset classes.
Capital IP has completed several transactions since the firm’s launch and are actively seeking and evaluating additional investment opportunities across a rapidly expanding opportunity pipeline. The firm’s senior partners previously invested over $1.2 billion in a variety of structured credit facilities, royalty monetizations, and the acquisition of “legacy” assets at their prior firms.
“We are excited to have formalized a committed line of capital with one of our limited partners, who has been a long-time supporter and participant in our investments” said Aron Dantzig, the firm’s founder and a Managing Partner. “We believe that our innovative approach to providing growth capital to emerging companies offers a real alternative in today’s volatile capital markets.
“Access to cost-efficient capital continues to pose a challenge for many emerging-growth companies, especially those with a deep base of underlying assets and misunderstood inherent value,” added Managing Partner Riyad Shahjahan. “We are seeing strong demand for our type of non-traditional, minimally dilutive capital in both the technology and life sciences sectors.”